A Dual Perspective: The Commercial and Clinical Future in the US

In this blog series, we celebrate Senzime's 25-year anniversary by reflecting on our past, present, and future.

Our US team leaders share their insights on the adoption of quantitative TOF monitoring in the U.S. market, its impact on patient safety, and our dedication to supporting customers nationwide.

By Jen Sanders, Clinical Director Senzime US

In the fast-paced world of healthcare, technological innovations are constantly reshaping clinical practice and patient outcomes. Among these advancements are high-quality, real-time, reliable quantitative train-of-four (TOF) monitors. At the forefront of that revolution is Senzime, answering the call with our EMG-based device, the TetraGraph system. 

Despite the perception that quantitative TOF monitoring is an emerging technology, it was developed through decades of rigorous research. With numerous anesthesia societies worldwide crafting practice guidelines on the monitoring and antagonism of neuromuscular block, the market is undergoing a profound shift. Quantitative monitors are no longer just an option; they're quickly becoming the new standard of care. 

Thanks to these strides, anesthesia is safer today than ever before, and that momentum is only poised to grow, especially in the United States. Looking ahead, I envision the TetraGraph system becoming ubiquitous on every continent and utilized whenever a neuromuscular blocking agent is administered. As we continue to witness the convergence of medicine and technology, the future of anesthetic care is bright. Being part of this transformative journey is undeniably exciting, and at the heart of it all is Senzime’s unwavering commitment to patient safety -- a cause I am proud to champion. 
 

By GW Hamilton, Commercial Vice President, Senzime US

Building a market in the medical device industry is a monumental task for even the most innovative and groundbreaking products. Building that market with disruptive technology that replaces an over-30-year-old standard of care is what many would call impossible. Well…welcome to Senzime! 

Where we make the impossible possible. It has been four years since we began this journey, and that journey started right at the beginning of a global pandemic that fundamentally shook up the U.S. healthcare system for over 2 years. Most would think it was the absolute worst time to launch a product, but looking back, it was the best time to do it. It really gave us the unique opportunity to work out the kinks, build a story, understand the challenges, and perfect our technology. It made us better. 

When we look back ten years from now, those two years will prove paramount in our success, and moving forward makes us formidable in really disrupting this market. We have guidelines as a tailwind, easing the burden of the constant headwinds we have faced. More and stronger research being published in this space, large national and regional benchmark accounts offering examples of successful implementation and engaged KOLs helping spread the message and guide the development of the future of EMG quantitative monitoring are all key pieces to our growing success. 

The success has yielded over triple-digit growth each year and produced record month after record month. This market is in the midst of a breakthrough. It is happening right in front of us, and we are firmly in the middle of its growth. I am so thrilled to be a part of this team and incredibly excited for our future.